ArticleTheranostics2017
Novel Linear Peptides with High Affinity to αvβ3 Integrin for Precise Tumor Identification.
Article in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 56 citations in OpenAlex.
- MD Simulation of Vector-Receptor Pharmacologic Pairs for Tumor-Specific Drug Delivery: Transfer of Boron Atoms by RGD Peptide to αvβ3 Integrin Receptor.Current issues in molecular biology · 2026Article
- Peptide-Functionalized Iron Oxide Nanoparticles for Cancer Therapy: Targeting Strategies, Mechanisms, and Translational Opportunities.Molecules (Basel, Switzerland) · 2026Review
- Exploration of potential novel drug targets for rheumatoid arthritis by plasma proteome screening.PLoS computational biology · 2025Article
- Preparation and preclinical evaluation ofEJNMMI radiopharmacy and chemistry · 2025Article
- Saddle curvature association of nsP1 facilitates the replication complex assembly of Chikungunya virus in cells.Nature communications · 2025Article
- Radioiodinated Bicyclic RGD Peptide Derivatives for Enhanced Tumor Accumulation.Pharmaceuticals (Basel, Switzerland) · 2025Article
- EGFR- and Integrin αInternational journal of molecular sciences · 2024Review
- Elevating theranostics: The emergence and promise of radiopharmaceutical cell-targeting heterodimers in human cancers.iRadiology · 2024Article
- PLGA-PEG-c(RGDfK)-IET nanobiotechnology · 2024Article
- Role of long non-coding RNAs in cancer: From subcellular localization to nanoparticle-mediated targeted regulation.Molecular therapy. Nucleic acids · 2023Review
- Advances in Surface Enhanced Raman Spectroscopy forNanotheranostics · 2022Review
- Synergic fabrication of succimer coated titanium dioxide nanomaterials delivery forDrug delivery · 2021Article
- Win, Lose, or Tie: Mathematical Modeling of Ligand Competition at the Cell-Extracellular Matrix Interface.Frontiers in bioengineering and biotechnology · 2021Article
- Article
- Engineering bacterial outer membrane vesicles as transdermal nanoplatforms for photo-TRAIL-programmed therapy against melanoma.Science advances · 2020Article
- Structure-Activity Relationship of RGD-Containing Cyclic Octapeptide and αvβ3 Integrin Allows for Rapid Identification of a New Peptide Antagonist.International journal of molecular sciences · 2020Article
- EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers.Theranostics · 2018Review
- Conserved Binding Regions Provide the Clue for Peptide-Based Vaccine Development: A Chemical Perspective.Molecules (Basel, Switzerland) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of alternative linear peptides for targeting αvβ3 integrin has attracted much attention, as the traditional peptide ligand, cyclic RGD, is limited by inferior water-solubility and complex synthesis. Using pharmacophore-based virtual screening and high-throughput molecular docking, we identified two novel linear small peptides RWr and RWrNM with high affinity and specificity to αvβ3 integrin. The competitive binding with cyclic RGD (c(RGDyK)) and cellular uptake related to the integrin expression levels verified their affinity to αvβ3 integrin. The intermolecular interaction measurement and dynamics simulation demonstrated the high binding affinity and stability, especially for RWrNM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.